Month: March 2018

Month: March 2018

Divestco and Bird River Resources Announce Cogeneration Joint Venture to Generate Low-Cost Electricity

CALGARY, Alberta, March 26, 2018 (GLOBE NEWSWIRE) — Divestco Inc. (TSX-V:DVT) (“Divestco”) and Bird River Resources Inc. (CSE:BDR) (“Bird River”) today announced a cogeneration joint venture (the “Cogen”) which will convert natural gas to electricity via a boiler-turbine at an industry low cost of 1.4 cents per kilowatt hour (based on current natural gas spot prices). Regulatory approvals are in place for the Cogen system to feed up to 3 megawatts of electricity into the power grid. The Cogen has secured a reliable, long-term gas supply through a privately owned natural gas producer. Construction and implementation of the project is expected to take 4-5 months.

Revive Therapeutics and Ehave Enter Into Patient Research Data Collaboration Agreement for Medical Cannabis Liver Disease Program

TORONTO, March 01, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”) (TSX-V:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, and Ehave, Inc. (“Ehave”) (OTCQB:EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, are pleased to announce that they have entered into a collaboration agreement to enable enhanced patient and clinical research data management for Revive’s research initiatives involving medical cannabis for the treatment of liver diseases.

Ehave Solutions Gain Traction in Cannabis Industry

SEATTLE, WA, March 07, 2018 (GLOBE NEWSWIRE) — CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering recent developments in the deployment of Ehave Inc.’s (OTCQB: EHVVF) Connect platform, an innovative bioinformatics tool that enables researchers, physicians, and patients to connect in a way that was never before possible. By bringing all of these parties together, everyone can work towards the common goal of improving patient outcomes on a highly personalized level.

Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

VANCOUVER, March 5, 2018 /CNW/ – Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB: EHVVF) (“Ehave”), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017. “Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially